Galectin-3 reduces the severity of pneumococcal pneumonia by augmenting neutrophil function.

The American Journal of Pathology
Sarah L FarnworthTariq Sethi

Abstract

The Gram-positive Streptococcus pneumoniae is the leading cause of community-acquired pneumonia worldwide, resulting in high mortality. Our in vivo studies show that galectin-3(-/-) mice develop more severe pneumonia after infection with S. pneumoniae, as demonstrated by increased bacteremia and lung damage compared to wild-type mice and that galectin-3 reduces the severity of pneumococcal pneumonia in part by augmenting neutrophil function. Specifically, we show that 1) galectin-3 directly acts as a neutrophil-activating agent and potentiates the effect of fMLP, 2) exogenous galectin-3 augments neutrophil phagocytosis of bacteria and delays neutrophil apoptosis, 3) phagocytosis of apoptotic neutrophils by galectin-3(-/-) macrophages is less efficient compared to wild type, and 4) galectin-3 demonstrates bacteriostatic properties against S. pneumoniae in vitro. Furthermore, ad-back of recombinant galectin-3 in vivo protects galectin-3-deficient mice from developing severe pneumonia. Together, these results demonstrate that galectin-3 is a key molecule in the host defense against pneumococcal infection. Therapeutic strategies designed to augment galectin-3 activity may both enhance inflammatory cell function (by directly affecti...Continue Reading

References

Feb 1, 1990·The American Review of Respiratory Disease·Y Sibille, H Y Reynolds
Jun 25, 1996·Proceedings of the National Academy of Sciences of the United States of America·R Y YangF T Liu
Feb 5, 1998·Biochemical Society Transactions·R C Hughes
Jan 5, 2000·Journal of Immunological Methods·C Dahlgren, A Karlsson
May 4, 2000·Microvascular Research·N FunakoshiT Mitsui
Aug 5, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·H SanoF T Liu
Feb 2, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sachiko SatoMichel G Bergeron
Sep 12, 2002·Biochimica Et Biophysica Acta·Douglas N W Cooper
Dec 4, 2002·Nature Reviews. Immunology·John SavillChris Haslett
Apr 15, 2003·Clinica Chimica Acta; International Journal of Clinical Chemistry·Stéphane WalrandMarie-Paule Vasson
Dec 25, 2003·Journal of Leukocyte Biology·Rachel BoxioOliver Nüsse
May 4, 2004·The Journal of Laboratory and Clinical Medicine·Charles Feldman
Dec 8, 2004·The Journal of Experimental Medicine·Astrid LanoueAndrew N J McKenzie
Mar 17, 2005·Journal of Medical Microbiology·G K PatersonT J Mitchell
Nov 2, 2005·Journal of Leukocyte Biology·Julie NieminenSachiko Sato
Feb 16, 2006·Biochimica Et Biophysica Acta·Jerka DumicMirna Flögel
May 20, 2006·The Journal of Clinical Investigation·Mark R LooneyMichael A Matthay
Sep 20, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Luciana KohatsuLinda G Baum
Feb 6, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Alison C MacKinnonTariq Sethi

❮ Previous
Next ❯

Citations

May 18, 2012·Cell and Tissue Research·John C GenselPhillip G Popovich
Aug 16, 2012·In Vitro Cellular & Developmental Biology. Animal·Sanja DabelicJerka Dumic
Dec 11, 2008·Immunologic Research·Adam D Kennedy, Frank R DeLeo
May 16, 2009·Nature Reviews. Microbiology·Gerardo R Vasta
Nov 9, 2011·Antimicrobial Agents and Chemotherapy·Christian St-PierreMichel J Tremblay
Dec 14, 2011·American Journal of Physiology. Gastrointestinal and Liver Physiology·Joy X JiangNatalie J Török
Dec 10, 2013·Respiratory Research·Peng GaoPeter G Gibson
Oct 28, 2011·PloS One·Marise Lopes FerminoLise Halbwachs-Mecarelli
Mar 16, 2013·Medical Mycology·Jennifer R LindenJoseph M Bliss
Aug 9, 2012·Chest·David H DockrellTimothy J Mitchell
Nov 3, 2009·Lancet·Tom van der Poll, Steven M Opal
Jul 15, 2009·Immunological Reviews·Neil C Henderson, Tariq Sethi
Feb 1, 2011·Arthritis and Rheumatism·Huamei ForsmanAnna Karlsson
Jul 26, 2012·Cellular Microbiology·Paola QuattroniRachel M Exley
Jan 13, 2012·Clinical and Experimental Immunology·M DemmertC Härtel
Feb 15, 2012·Annals of the New York Academy of Sciences·Fu-Tong LiuDaniel K Hsu
Feb 12, 2010·Annals of the New York Academy of Sciences·Fu-Tong Liu, Gabriel A Rabinovich
Apr 6, 2016·Cell Biology and Toxicology·Vinod Vijay Subhash, Bow Ho
Jun 24, 2015·European Journal of Pharmacology·Wouter C MeijersRudolf A de Boer
Sep 17, 2011·Immunology Letters·Barbara PlatzerEdda Fiebiger
Dec 31, 2014·Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology·Satwat Hashmi, Suhail Al-Salam
Jun 6, 2015·Military Medical Research·Yong YangJie Fan
Mar 4, 2014·Current Opinion in Microbiology·Huan-Yuan ChenFu-Tong Liu
Sep 9, 2011·Immunobiology·Billur BaserasGertrud Maria Hänsch
Oct 12, 2014·Glycobiology·Giuseppe PuglieseStefano Menini
May 31, 2016·Joint, Bone, Spine : Revue Du Rhumatisme·Yong HuPascal Reboul
Apr 9, 2009·PLoS Neglected Tropical Diseases·Sasisekhar BennuruThomas B Nutman
Sep 14, 2016·Biochemical and Biophysical Research Communications·Kerstin A HeylHortense Slevogt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

Immunological Reviews
Neil C Henderson, Tariq Sethi
Clinical and Experimental Immunology
M DemmertC Härtel
Allergology International : Official Journal of the Japanese Society of Allergology
Yumiko NishiKoji Shirai
© 2021 Meta ULC. All rights reserved